Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Pfizer entered an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases.
- Starna will receive $330 million upfront, along with up to $2.3 billion in potential milestones and royalties on net sales.…
Disclaimer
  • Pfizer entered an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. * Starna will receive $330 million upfront, with eligibility for up to $2.3 billion in milestones and royalties on approved products’ net sales. * The agreement grants exclusive development, manufacturing and commercialization rights outside Greater China, with options to expand into Greater China. * The deal includes technology rights in immunology and oncology, with options to exclusively license compounds from a separate research collaboration. * The drugmaker will lead clinical development outside Greater China, using its US facilities to manufacture finished products for initial trials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261118535937) on November 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.